2907-85-9

Basic information

• Product Name: (2-Oxotetrahydrofuran-3-yl)phosphonic acid diethyl ester
• Synonyms: (2-Oxotetrahydrofuran-3-yl)phosphonic acid diethyl ester;3-(Diethoxyphosphinyl)-4,5-dihydrofuran-2(3H)-one;3-(Diethoxyphosphinyl)oxolane-2-one
• CAS NO: 2907-85-9
• Molecular Formula: C₈H₁₅O₅P
• Molecular Weight: 222.1755
• Mol File: 2907-85-9.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 366.2°Cat760mmHg
• Flash Point: 188.9°C
• Appearance: /
• Density: 1.2g/cm³
• Vapor Pressure: 1.49E-05mmHg at 25°C
• Refractive Index: 1.443
• CAS DataBase Reference: (2-Oxotetrahydrofuran-3-yl)phosphonic acid diethyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: (2-Oxotetrahydrofuran-3-yl)phosphonic acid diethyl ester(2907-85-9)
• EPA Substance Registry System: (2-Oxotetrahydrofuran-3-yl)phosphonic acid diethyl ester(2907-85-9)

Safety Data

• Hazardous Substances Data: 2907-85-9(Hazardous Substances Data)

Usage

General Description

(2-Oxotetrahydrofuran-3-yl)phosphonic acid diethyl ester is a chemical compound that is commonly used as a reagent in organic synthesis. It is a diethyl ester derivative of (2-oxotetrahydrofuran-3-yl)phosphonic acid, and it possesses a phosphonic acid functional group, making it useful in the formation of phosphonate esters. (2-Oxotetrahydrofuran-3-yl)phosphonic acid diethyl ester is known for its potential application in the development of pharmaceuticals, agrochemicals, and materials science, due to its versatile reactivity and ability to participate in various chemical reactions. Additionally, it has been studied for its potential as a ligand in coordination chemistry due to the presence of the phosphonic acid group.

InChI:InChI=1/C8H15O5P/c1-3-12-14(10,13-4-2)7-5-6-11-8(7)9/h7H,3-6H2,1-2H3

Upstream product

• 5061-21-2 α-bromo-γ-butyrolactone 
• 122-52-1 triethyl phosphite 
• 96-48-0 4-butanolide 
• 814-49-3 diethyl chlorophosphate 
• 589-57-1 diethyl phosphorylchloridite 

Downstream Products

• 52216-89-4 (Z)-α-propylidene-γ-butyrolactone 
• 52216-90-7 (E)-α-propylidene-γ-butyrolactone 
• 1400289-29-3 diethyl (3-(bis(4-methoxy-3-methylphenyl)methyl)-2-oxotetrahydrofuran-3-yl)phosphonate 
• 365532-28-1 3-(1-benzylpiperidin-4-ylidene)dihydrofuran-2-one 
• 6285-99-0 (E)-benzylidenedihydro-2(3H)-furanone 
• 444760-00-3 3-[(4Z,6E)-(2R,3S)-3-(tert-Butyl-dimethyl-silanyloxy)-2,4,6-trimethyl-7-(4-nitro-phenyl)-hepta-4,6-dien-(Z)-ylidene]-dihydro-furan-2-one 

Relevant articles and documents

Stereocontrol in Horner-Wadsworth-Emmons Condensations of α-Phosphono Lactones with Aldehydes: A Synthesis of Integerrinecic Acid and Senecic Acid Lactones

The Horner-Wadsworth-Emmons condensations of α-phosphono lactones were investigated under a variety of conditions.Upon treatment with KHMDS and 18-crown-6 in THF, condensations of the five-membered ring phosphono lactones 7a and 8 with propionaldehyde afforded the E olefins cleanly.In contrast, these phosphonates gave predominantly the Z olefins upon treatment with propionaldehyde, K2CO3 and 18-crown-6 in THF.A similar, though somewhat less-pronounced trend was observed with the six-membered ring phosphono lactone 9a.However, in its condensation with acetaldehyde the more functionalized phosphono lactone 4 gave the best E selectivity (ca. 9:1) when DBU/CH3CN was used, providing the methyl ester of integerrinecic acid lactone (5) in 77percent isolated yield.When K2CO3/18-crown-6/toluene was employed in a parallel reaction, only slight selectivity for the Z isomer was observed, but the methyl ester of senecic acid lactone (6) still was obtained in 43-46percent yield from the product mixture.

Novel synthesis of physovenine and physostigmine analogs

This Letter describes a versatile synthetic approach to prepare physovenine and physostigmine analogs. A series of analogs were synthesized and evaluated for cholinesterase inhibition activities, including human acetylcholinesterase (AChE) and butyrylchol

7-AMINO ALKYLIDENYL-HETEROCYCLIC QUINOLONES AND NAPHTHYRIDONES

The present invention relates to compounds having a structure according to Formula I wherein n, m, z, R, R2, R3, R4, R5, R6, A, E, X, Y a and b are as defined above; or an optical isomer, diastereomer or enantiomer thereof; a pharmaceutically acceptable s